Occam is pleased to announce the placement of Ellen Lubman as CBO at Werewolf Therapeutics, an MPM-backed oncology platform company. After emerging from stealth mode last year with a $56M raise, Werewolf is poised to rapidly advance multiple programs into the clinic this year.

In Lubman, Werewolf captures a richly experienced business development executive with an elevated strategic mind, virtues that will serve the company well as it seeks to deliver on the potential of its robust immunomodulatory platform